Morita–Baylis–Hillman adducts and their derivatives: a patent-based exploration of diverse biological activities

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Basavaiah D, Naganaboina RT. The Baylis–Hillman reaction: a new continent in organic chemistry – our philosophy, vision and over three decades of research. New J. Chem. 42(17), 14036–14066 (2017). •• Provide a concise summary of the philosophical perspective on the history and development of the MBH reaction by one of the foremost authorities in the field.
  Google Scholar
• 2. Basavaiah D, Reddy GC. Intramolecular Baylis-Hillman reaction: synthesis of heterocyclic molecules. ARKIVOC: Online Journal of Organic Chemistry ii, 172–205 (2016).
  Google Scholar
• 3. Correia PRS, Freitas JD, Zeoly LA, Porto RS, Lima DJP. Discovery and structure-activity relationship of Morita–Baylis–Hillman adducts as larvicides against dengue mosquito vector, Aedes aegypti (Diptera: culicidae). Bioorg. Med. Chem. 117315 (2023).
  MedlineGoogle Scholar
• 4. Coelho F, Almeida WP. The Baylis-Hillman reaction: a strategy for the preparation of multifunctionalised intermediates for organic synthesis. Química nova 23, 98–101 (2000).
  CASGoogle Scholar
• 5. Zhong W, Liu Y, Wang G et al. Recent advances in construction of nitrogen-containing heterocycles from Baylis-Hillman adducts. Org. Prep. Proc. Int. 43(1), 1–66 (2011).
  Google Scholar
• 6. Zhu H, Shao N, Chen T, Zou H. Functionalized heterocyclic scaffolds derived from Morita–Baylis–Hillman acetates. Chem. Commun. 49(70), 7738–7740 (2013).
  Medline CASGoogle Scholar
• 7. Selig P, Turočkin A, Raven W. Guanidine-Catalyzed γ-Selective Morita–Baylis–Hillman Reactions on α, γ- Dialkyl-Allenoates: Access to Densely Substituted Heterocycles. Synlett 24(19), 2535–2539 (2013).
  CASGoogle Scholar
• 8. Reddy YS, Kadigachalam P, Basak RK, Pal AJ, Vankar YD. Total synthesis of (+)-pericosine B and (+)-pericosine C and their enantiomers by using the Baylis–Hillman reaction and ring-closing metathesis as key steps. Tetrahedron Lett. 53(2), 132–136 (2012).
  CASGoogle Scholar
• 9. Yuan P, Gaich T. Enantioselective total synthesis of (+)-Pepluanol A. Org. Lett. 24(26), 4717–4721 (2022).
  Medline CASGoogle Scholar
• 10. Bhowmik S, Batra S. Morita–Baylis–Hillman approach toward formal total synthesis of Tamiflu and total synthesis of gabaculine. Eur. J. Org. Chem. 2013(31), 7145–7151 (2013).
  CASGoogle Scholar
• 11. Dunn PJ, Hughes ML, Searle PM, Wood AS. The chemical development and scale-up of sampatrilat1. Org. Process Res. Dev. 7(3), 244–253 (2003). • Reports the process of scaling up the production of a significant MBH-derived ACE inhibitor, showcasing its immense potential for industrial applications.
  CASGoogle Scholar
• 12. Wani MM, Dar AA, Bhat BA. Micelle-guided Morita–Baylis–Hillman reaction of ketones in water. Org. Biomol. Chem. 20(24), 4888–4893 (2022).
  Medline CASGoogle Scholar
• 13. Pereira MP, de Souza Martins R, de Oliveira MAL, Bombonato FI. Amino acid ionic liquids as catalysts in a solvent-free Morita–Baylis–Hillman reaction. RSC Advances 8(42), 23903–23913 (2018).
  Medline CASGoogle Scholar
• 14. Bharadwaj KC. Intramolecular Morita–Baylis–Hillman and Rauhut–Currier reactions. A catalytic and atom economic route for carbocycles and heterocycles. RSC Advances 5(93), 75923–75946 (2015).
  Google Scholar
• 15. Lima–Junior CG, Vasconcellos ML. Morita–Baylis–Hillman adducts: biological activities and potentialities to the discovery of new cheaper drugs. Bioorg. Med. Chem. 20(13), 3954–3971 (2012).
  Medline CASGoogle Scholar
• 16. Bhowmik S, Batra S. Applications of Morita–Baylis–Hillman reaction to the synthesis of natural products and drug molecules. Curr. Org. Chem. 18(24), 3078–3119 (2014).
  CASGoogle Scholar
• 17. Elleuch H, Mihoubi W, Mihoubi M, Ketata E, Gargouri A, Rezgui F. Potential antioxidant activity of Morita- Baylis-Hillman adducts. Bioorg. Chem. 78, 24–28 (2018).
  Medline CASGoogle Scholar
• 18. Chang L, Thorimbert S, Dechoux L. The bio-based methyl coumalate involved Morita–Baylis–Hillman reaction. Org. Biomol. Chem. 17(10), 2784–2791 (2019).
  Medline CASGoogle Scholar
• 19. Haleem A, Ullah H, Samiullah Akbar A, Ahmad N, Ellahi M, Nawaz M. Synthesis and biological activity of morita baylis hillman adducts and their oximes. Pharm. Chem. J. 56(2), 185–190 (2022).
  CASGoogle Scholar
• 20. Ferreira LAMP, de Lima LM, Ferreira LKDP et al. Biological activities of Morita–Baylis–Hillman adducts (MBHA). Mini-Rev. Med. Chem. 23(17), 1691–1710 (2023). •• Describing a recent and comprehensive review, this article highlights the biological activities of MBH adducts documented in the literature.
  MedlineGoogle Scholar
• 21. Mattiuzzi C, Lippi G. Current cancer epidemiology. J. Epidemiol. Glob. Health 9(4), 217 (2019). • Provides a succinct summary of the current cancer epidemiology and furnishes up-to-date data on the incidence, mortality and survival rates for the top 15 types of cancers globally
  MedlineGoogle Scholar
• 22. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 23. Habib SH, Saha S. Burden of non-communicable disease: global overview. Diabetes & metabolic syndrome. Clin Res Rev. 4(1), 41–47 (2010).
  Google Scholar
• 24. Alzahrani SM, Al Doghaither HA, Al Ghafari AB. General insight into cancer: an overview of colorectal cancer. Mol Clin Oncol. 15(6), 1–8 (2021).
  Google Scholar
• 25. Zhu H, Swami U, Preet R, Zhang J. Harnessing DNA replication stress for novel cancer therapy. Genes 11(9), 990 (2020).
  Medline CASGoogle Scholar
• 26. Lee CH, Jung HJ, Kim SG et al. KR20060035091 A (2006).
  Google Scholar
• 27. Furdas SD, Kannan S, Sippl W, Jung M. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Archiv der Pharmazie 345(1), 7–21 (2012).
  Medline CASGoogle Scholar
• 28. Adimulam T, Arumugam T, Foolchand A, Ghazi T, Chuturgoon AA. The effect of organoselenium compounds on histone deacetylase inhibition and their potential for cancer therapy. International Journal of Molecular Sciences 22(23), 12952 (2021).
  Medline CASGoogle Scholar
• 29. Ma L, Bian X, Lin W. The dual HDAC-PI3 K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. J. Exp. Clin. Cancer Res. 39(1), 1–14 (2020).
  MedlineGoogle Scholar
• 30. Ganai SA, Sheikh FA, Baba ZA. Plant flavone Chrysin as an emerging histone deacetylase inhibitor for prosperous epigenetic‐based anticancer therapy. Phytotherapy Research 35(2), 823–834 (2021).
  Medline CASGoogle Scholar
• 31. Lee CH, Jung HJ, Kim JH et al. KR100711944B1 (2007).
  Google Scholar
• 32. Price RN. Artemisinin drugs: novel antimalarial agents. Expert Opin. Investig. Drugs 9(8), 1815–1827 (2000).
  Medline CASGoogle Scholar
• 33. Slezáková S, Ruda-Kucerova J. Anticancer activity of artemisinin and its derivatives. Anticancer Res. 37(11), 5995–6003 (2017).
  Medline CASGoogle Scholar
• 34. Baisha G, Barua NC, Goswami A et al. WO2011089507A1 (2011).
  Google Scholar
• 35. Krishna PR, Reddy PN, Sreeshailam A, Kiran MU, Jagdeesh B. The Baylis–Hillman reaction: a strategic tool for the synthesis of higher-carbon sugars. Tetrahedron Letters 48(37), 6466–6470 (2007).
  CASGoogle Scholar
• 36. Zhang L, Huo X, Liao Y, Yang F, Gao L, Cao L. Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways. Sci. Rep. 7(1), 1–13 (2017).
  MedlineGoogle Scholar
• 37. Zhang L, Jin J, Zhang L et al. Quantitative analysis of differential protein expression in cervical carcinoma cells after zeylenone treatment by stable isotope labeling with amino acids in cell culture. J. Proteom. 126, 279–287 (2015).
  Medline CASGoogle Scholar
• 38. Huo X, Liao Y, Tian Y, Gao L, Cao L. Zeylenone promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving Jak2 and Src kinase. RSC Adv. 6(115), 114096–114108 (2016).
  CASGoogle Scholar
• 39. Xu X, Sun Z, Cao L, Tian Y, Yang S. CN112409183 B (2022).
  Google Scholar
• 40. Zhong W, Shao B, Xiao X, Ling F. CN112939999 B (2022).
  Google Scholar
• 41. Mou J, Li L, Zhou T, Yang R, Xiang R, Pei D. CN112300106 B (2023).
  Google Scholar
• 42. Sabatino A, Regolisti G, Cosola C, Gesualdo L, Fiaccadori E. Intestinal microbiota in type 2 diabetes and chronic kidney disease. Current Diabetes Reports 17, 1–9 (2017).
  Medline CASGoogle Scholar
• 43. Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell. Mol. Life Sci. 69, 741–762 (2012).
  Medline CASGoogle Scholar
• 44. Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutrition Journal 13, 1–10 (2014).
  MedlineGoogle Scholar
• 45. Jung JH, Zhiran J. KR102072378B1 (2020).
  Google Scholar
• 46. Chavez-Dominguez R, Perez-Medina M, Aguilar-Cazares D et al. Old and new players of inflammation and their relationship with cancer development. Front. Oncol. 11, 722999 (2021).
  Medline CASGoogle Scholar
• 47. Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell. Mol. Immunol. 13(3), 267–276 (2016).
  Medline CASGoogle Scholar
• 48. Oguntibeju OO. Medicinal plants with anti-inflammatory activities from selected countries and regions of Africa. J. Inflamm. Res. 307–317 (2018).
  MedlineGoogle Scholar
• 49. Baj T, Seth R. Role of curcumin in regulation of TNF-α mediated brain inflammatory responses. Recent Pat Inflamm Allergy Drug Discov. 12(1), 69–77 (2018).
  Medline CASGoogle Scholar
• 50. Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem. Pharmacol. 180, 114147 (2020).
  Medline CASGoogle Scholar
• 51. Mascarenhas SR, Silva JSF, Lima EA et al. BR102021015691-0A2 (2023).
  Google Scholar
• 52. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 3(2), 47 (2006).
  MedlineGoogle Scholar
• 53. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 348, g3308 (2014).
  MedlineGoogle Scholar
• 54. Zheng ZB, D'Andrea S. US8716275B2 (2014).
  Google Scholar
• 55. Doron S, Gorbach SL. Bacterial infections: overview. Int. Enc. Publ. Health 2008, 273–282 (2008).
  Google Scholar
• 56. Porto VA, dos Santos Correia PR, Porto RS. Synthesis and antibacterial activity of 2-mercaptobenzimidazole derivatives: a literature review. Rev. Virtual Quim. 13(6), 1457–1466 (2021).
  CASGoogle Scholar
• 57. Wei W, Cheng P, Bo H et al. CN104774155 A (2015).
  Google Scholar
• 58. Doehlemann G, Ökmen B, Zhu W, Sharon A. Plant pathogenic fungi. Microbiol. Spectr. 5(1), 5–1 (2017).
  Google Scholar
• 59. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 18(5), 195–204 (2010). •• Offers an overview of the present state of drug therapy for invasive fungal diseases, along with key areas of focus for future advancements in the development of new compounds.
  Medline CASGoogle Scholar
• 60. Anderson R, Lee SF, Du V, Hokama T, Oey R, Arakaki P. WO2005115148A1 (2005).
  Google Scholar
• 61. Kim JM, Kim KH, Kim TH, Kim JN. The first successful intermolecular Heck reaction of Baylis–Hillman adducts: synthesis of β-aryl substituted Baylis–Hillman adducts. Tetrahedron Lett. 49(20), 3248–3251 (2008).
  CASGoogle Scholar
• 62. Xie JW, Li D, Wei PS. CN105777773 A (2015).
  Google Scholar
• 63. Wei PS, Wang MX, Xu DC, Xie JW. Synthesis of 2, 3-Dihydrothieno (2, 3-b) quinolines and Thieno (2, 3-b)- quinolines via an Unexpected Domino Aza-MBH/Alkylation/Aldol Reaction. J. Org. Chem. 81(3), 1216–1222 (2016).
  Medline CASGoogle Scholar
• 64. Dos Santos MS, Coelho FAS, Schreiber AZ, Fernandes LL, De Carvalho JA, Ruiz ALT. BR102017018013-1 A2 (2017).
  Google Scholar
• 65. Moye-Rowley WS. Linkage between genes involved in azole resistance and ergosterol biosynthesis. PLoS Pathog 16(9), e1008819 (2020). • Examines in detail the mechanism of action associated with resistance to azole antifungals
  Medline CASGoogle Scholar
• 66. Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin. Pharmacother. 19(9), 971–977 (2018).
  Medline CASGoogle Scholar
• 67. White NJ. Antimalarial drug resistance. J. Clin. Invest. 113(8), 1084–1092 (2004).
  Medline CASGoogle Scholar
• 68. Puli N, Banda G, Uppalanchi S et al. WO2007032016A1 (2007).
  Google Scholar
• 69. Eustache J, Boiteau JG, Tarnus C, Rodeschini V, Van de Weghe P. WO03040119A1 (2003).
  Google Scholar
• 70. Lee S-F, Hokama T, Anderson R. WO2005123727A1 (2005).
  Google Scholar
• 71. Neamati N, Kabalka G, Venkataiah B, Dayam R. WO2007081966A2 (2007).
  Google Scholar
• 72. Yu CX. CN1315778 C (2007).
  Google Scholar
• 73. Wurtz NR, Priestley ES, Cheney DL, Zhang X, Parkhurst B, Ladziata V. WO2008079759A1 (2008).
  Google Scholar
• 74. Lee CH, Jung HJ, Kim JH et al. WO2008054154A1 (2008).
  Google Scholar
• 75. Chattopadhyaya J, Upadhyaya RS. WO2009091324A1 (2009).
  Google Scholar
• 76. Ryu DH, Hwang GS, Kim KH, Park JH, Kim HJ. WO2009110655A1 (2009).
  Google Scholar
• 77. Mcguire H, Bist S, Bifulco N et al. WO2013150296A1 (2013).
  Google Scholar
• 78. Chen L, Jones ED, Ma D et al. CN101990536 B (2014).
  Google Scholar
• 79. Vishwakarma RA, Bharate SB, Bhushan S et al. WO2014170914A1 (2014).
  Google Scholar
• 80. Ramesh V, Rani PU, Rao VJ, Ramesh V, Rani PU, Rao VJ. WO2017109795A1 (2017).
  Google Scholar
• 81. Kumar J, Mahendar B, Saidulu M, Banerjee SK, Rao VJ. WO2017072796A1 (2017).
  Google Scholar
• 82. Fuentefria AM, Braga AL, Batista BG et al. BR102017015184A2 (2019).
  Google Scholar
• 83. Zajdel P, Drop M, Canale V et al. WO2020117075A1 (2020).
  Google Scholar
• 84. Ramachandran PV, Seleen M. WO2022204231A2 (2022).
  Google Scholar
• 85. Pelegrini C, Fornai M, Antonioli L et al. WO2022234447A1 (2022).
  Google Scholar
• 86. Hou W, Lan J, Huang H, Xu X, Huang L. CN115721652 A (2023).
  Google Scholar